Development of deuterium metabolic imaging to map body biochemistry with MRI

Informations projet

BodyDMI

N° de convention de subvention: 850488

DOI

10.3030/850488

Projet clôturé

Date de signature de la CE 3 Mai 2019

Date de début 1 Juin 2019

Date de fin 31 Mai 2021

Financé au titre de

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Coût total

€ 100 000,00

Contribution de l’UE

€ 100 000,00

Coordonné par

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands

Periodic Reporting for period 1 - BodyDMI (Development of deuterium metabolic imaging to map body biochemistry with MRI)

Période du rapport: 2019-06-01 au 2021-05-31

Résumé du contexte et des objectifs généraux du projet

The global obesity epidemic has resulted in a dramatic rise in metabolic diseases and the development of effective therapies has greatly lagged behind. This could arguably be attributed to a lack of non-invasive (imaging) techniques to characterize disturbances in metabolic pathways. We will investigate the use of dynamic deuterium metabolic imaging (DMI) to dynamically map body biochemistry in humans in 3D imaging mode. DMI relies on deuterium magnetic resonance spectroscopic imaging combined with oral administration of deuterium-labeled compounds.
The innovation idea is linked to the MCUBE project of FET-OPEN-01-2016-2017. Here a dual-dipole coil was designed for hydrogen MRI at 7 tesla (300 MHz), which outperformed the state-of-the-art setup of the loop-dipole coil for MRI. The new design is transparent to loop designs, meaning that the setup can be combined with loop coils, which are known to be the optimal setup for low frequency operation. So for DMI, which operates at 45.7 MHz (low frequency) at 7 tesla, an MRI coil array can be designed that not only outperforms MRI, but also enables DMI at uncompromised sensitivity within the same scan session, which will complement the utilization of the MCUBE project.
The objectives of the project are: (1) Build and test a body DMI setup for a clinical ultra-high field 7 tesla MRI scanner; (2) demonstrate proof of concept to measure hepatic carbohydrate and lipid metabolism with DMI; and (3) apply DMI in a clinical feasibility study in type 2 diabetes patients.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

We have successfully constructed a multi-channel body array coil for DMI and a preproduction model has been designed. The setup provided excellent sensitivity and good signal stability, allowing for dynamic measurements. We successfully showed the application of 3D DMI for dynamic and spatially-resolved monitoring of deuterated glucose uptake and metabolism throughout the human body. DMI will be valorized by the commercial partners and embedded in clinical practice. Besides its application in metabolic diseases, DMI has potential to detect for example effects of cancer treatment in a much earlier stage than morphological imaging. We have preparing clinical research studies on the application of DMI to assess therapy response in both diabetes and cancer.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

As metabolic alterations precede any morphologic alterations during disease manifestation or during treatments, DMI will improve patient diagnostics (earlier recognition of disease) and improve treatment monitoring (i.e. ineffective treatments can be stopped much earlier and replaced by alternative treatments). Moreover, direct detection of metabolism will be beneficial for drug development, opening up a new area of research and development in drug discoveries.

Dynamic deuterium metabolic imaging of deuterated glucose in the body